Table 2.
XGBoost | NRI (95% CI) | IDI (95% CI) | |||||
---|---|---|---|---|---|---|---|
<2.5% | 2.5–4.9% | ≥5% | Total | ||||
Refitted China-PAR | |||||||
Non-case | <2.5% | 14 142 | 270 | 74 | 14 486 | 0.0386 | 0.0174 |
2.5–4.9% | 2119 | 2506 | 323 | 4948 | (0.0135, 0.0638) | (0.0135, 0.0212) | |
≥5% | 53 | 1183 | 3577 | 4813 | |||
Total | 16 314 | 3959 | 3974 | 24 247 | |||
Case | <2.5% | 185 | 11 | 8 | 204 | ||
2.5–4.9% | 46 | 114 | 20 | 180 | |||
≥5% | 1 | 62 | 522 | 585 | |||
Total | 232 | 187 | 550 | 969 |
LASSO | |||||||
---|---|---|---|---|---|---|---|
<2.5% | 2.5–4.9% | ≥5% | Total | ||||
Refitted China-PAR | |||||||
Non-case | <2.5% | 14 147 | 324 | 15 | 14 486 | 0.0278 | 0.0106 |
2.5–4.9% | 1057 | 3543 | 348 | 4948 | (0.0066, 0.0489) | (0.0081, 0.0131) | |
≥5% | 3 | 826 | 3984 | 4813 | |||
Total | 15 207 | 4693 | 4347 | 24 247 | |||
Case | <2.5% | 188 | 14 | 2 | 204 | ||
2.5–4.9% | 22 | 132 | 26 | 180 | |||
≥5% | 0 | 41 | 544 | 585 | |||
Total | 210 | 187 | 572 | 969 |
aThe results are given based on the subjects who were not censored (25 216) from the validation set of 31 544.